gefitinib has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ao, Y; Fukumoto, H; Kuroki, T; Mori, M; Naruse, I; Nishio, K; Ohmori, T; Saijo, N | 1 |
1 other study(ies) available for gefitinib and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; K562 Cells; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphorylation; Quinazolines; RNA, Neoplasm; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2002 |